MXPA03005257A - Composiciones frarmaceuticas de un agonista del receptor de nmda. - Google Patents

Composiciones frarmaceuticas de un agonista del receptor de nmda.

Info

Publication number
MXPA03005257A
MXPA03005257A MXPA03005257A MXPA03005257A MXPA03005257A MX PA03005257 A MXPA03005257 A MX PA03005257A MX PA03005257 A MXPA03005257 A MX PA03005257A MX PA03005257 A MXPA03005257 A MX PA03005257A MX PA03005257 A MXPA03005257 A MX PA03005257A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
receptor agonist
nmda receptor
agonist pharmaceutical
nmda
Prior art date
Application number
MXPA03005257A
Other languages
English (en)
Inventor
Jinyang Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA03005257A publication Critical patent/MXPA03005257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03005257A 2000-12-13 2001-12-05 Composiciones frarmaceuticas de un agonista del receptor de nmda. MXPA03005257A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
BO0102359 2001-12-05

Publications (1)

Publication Number Publication Date
MXPA03005257A true MXPA03005257A (es) 2003-09-25

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005257A MXPA03005257A (es) 2000-12-13 2001-12-05 Composiciones frarmaceuticas de un agonista del receptor de nmda.

Country Status (42)

Country Link
US (2) US6635270B2 (es)
EP (1) EP1347760B1 (es)
JP (1) JP2004515529A (es)
KR (1) KR100533407B1 (es)
CN (1) CN1273135C (es)
AP (1) AP1235A (es)
AR (1) AR035607A1 (es)
AT (1) ATE296629T1 (es)
AU (2) AU2002218454B2 (es)
BG (1) BG107788A (es)
BR (1) BR0116085A (es)
CA (1) CA2431172A1 (es)
CZ (1) CZ20031543A3 (es)
DE (1) DE60111265T2 (es)
DO (1) DOP2001000300A (es)
DZ (1) DZ3484A1 (es)
EA (1) EA006489B1 (es)
EC (1) ECSP034655A (es)
EE (1) EE200300284A (es)
ES (1) ES2239648T3 (es)
GE (1) GEP20053568B (es)
HK (1) HK1059575A1 (es)
HR (1) HRP20030473A2 (es)
HU (1) HUP0400645A2 (es)
IL (1) IL155810A0 (es)
IS (1) IS6811A (es)
MA (1) MA26970A1 (es)
MX (1) MXPA03005257A (es)
NO (1) NO20032678D0 (es)
NZ (1) NZ525742A (es)
OA (1) OA12414A (es)
PA (1) PA8534901A1 (es)
PE (1) PE20020710A1 (es)
PL (1) PL362080A1 (es)
PT (1) PT1347760E (es)
SK (1) SK6982003A3 (es)
TN (1) TNSN01173A1 (es)
UA (1) UA73619C2 (es)
UY (1) UY27068A1 (es)
WO (1) WO2002047685A2 (es)
YU (1) YU41103A (es)
ZA (1) ZA200303892B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
RU2515615C2 (ru) 2008-09-18 2014-05-20 Нортвестерн Юниверсити Модуляторы нмда-рецептора и их применения
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
MX2012009388A (es) 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014120783A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2016506961A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CA2898774C (en) 2013-01-29 2021-07-13 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105934247A (zh) * 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) * 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
TR199800208T1 (es) * 1995-08-11 1998-05-21 Pfizer Inc.
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
JP2004515529A (ja) 2004-05-27
KR20030070060A (ko) 2003-08-27
ES2239648T3 (es) 2005-10-01
DE60111265T2 (de) 2006-05-04
IL155810A0 (en) 2003-12-23
CN1479617A (zh) 2004-03-03
WO2002047685A2 (en) 2002-06-20
EP1347760B1 (en) 2005-06-01
CN1273135C (zh) 2006-09-06
MA26970A1 (fr) 2004-12-20
US20020111366A1 (en) 2002-08-15
EA006489B1 (ru) 2005-12-29
SK6982003A3 (en) 2004-08-03
TNSN01173A1 (fr) 2005-11-10
DE60111265D1 (de) 2005-07-07
UY27068A1 (es) 2002-07-31
CZ20031543A3 (cs) 2004-06-16
HUP0400645A2 (hu) 2004-06-28
EE200300284A (et) 2003-10-15
CA2431172A1 (en) 2002-06-20
UA73619C2 (en) 2005-08-15
BG107788A (bg) 2004-01-30
PL362080A1 (en) 2004-10-18
PA8534901A1 (es) 2002-08-26
EP1347760A2 (en) 2003-10-01
GEP20053568B (en) 2005-07-11
PT1347760E (pt) 2005-09-30
NO20032678L (no) 2003-06-12
NZ525742A (en) 2005-07-29
US6635270B2 (en) 2003-10-21
WO2002047685A3 (en) 2002-08-15
AR035607A1 (es) 2004-06-16
ZA200303892B (en) 2004-05-20
ECSP034655A (es) 2003-07-25
BR0116085A (pt) 2003-12-23
KR100533407B1 (ko) 2005-12-02
PE20020710A1 (es) 2002-08-09
IS6811A (is) 2003-05-08
NO20032678D0 (no) 2003-06-12
HK1059575A1 (en) 2004-07-09
HRP20030473A2 (en) 2005-04-30
AP2001002376A0 (en) 2001-12-31
DOP2001000300A (es) 2002-05-30
US20040039022A1 (en) 2004-02-26
AU2002218454B2 (en) 2005-10-27
EA200300514A1 (ru) 2003-10-30
YU41103A (sh) 2006-05-25
OA12414A (en) 2006-04-18
DZ3484A1 (fr) 2002-06-20
AU1845402A (en) 2002-06-24
AP1235A (en) 2004-01-06
ATE296629T1 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
MXPA02002546A (es) Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.
ZA200003998B (en) Pharmaceutical compositions.
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
MXPA03003235A (es) Formulaciones farmaceuticas de liberacion retrasada.
HUP0301777A3 (en) Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
HUP0300541A3 (en) Pharmaceutical compositions for sustained release, containing fluvastatin
EP1436258A4 (en) ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
AU2001296013A1 (en) Pgd2 receptor antagonistic pharmaceutical compositions
ZA200210359B (en) Pharmaceutical compositions.
HUP0300419A3 (en) Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
EP1296958A4 (en) ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
MXPA03002105A (es) Composiciones farmaceuticas.
HK1042699A1 (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists.
AU2002335093A1 (en) Nr3b nmda receptor subunit compositions and related methods
HUP0200057A2 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
IL152205A0 (en) A solid dispersion, pharmaceutical compositions containing the same and methods for the preparation thereof
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
IL154414A0 (en) Pharmaceutical compositions containing an indolinyl-2,2-dimethylpropanamide
GB0015901D0 (en) Compositions containing 5ht receptor agonists
ZA200005850B (en) β2- Adrenergic receptor agonists.

Legal Events

Date Code Title Description
FG Grant or registration